Sunitinib—a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor
Maria Debiec-Rychter
Correspondence Department of Human Genetics, Catholic University of Leuven, Herestraat 49, B–3000 Leuven, Belgium
Email maria.debiec-rychter@med.kuleuven.be
This article has no abstract so we have provided the first paragraph of the full text.
The vast majority of GISTs aberrantly express constitutively activated forms of the KIT tyrosine kinase receptor. In 80–85% of GISTs, oncogenic mutations in the extracellular and juxtamembrane domains of the KIT receptor (encoded by KIT exons 9 and 11, respectively) are responsible for the constitutive kinase activity. A smaller subset of tumors (5–7%) harbor mutations in the KIT-related PDGFRA gene.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.